Pharmacology of human trace amine‐associated receptors: Therapeutic opportunities and challenges☆

  title={Pharmacology of human trace amine‐associated receptors: Therapeutic opportunities and challenges☆},
  author={Mark D. Berry and R. R. Gainetdinov and Marius C. Hoener and Mohammed Shahid},
  journal={Pharmacology \& Therapeutics},

Figures and Tables from this paper

Trace amine-associated receptor 1: a multimodal therapeutic target for neuropsychiatric diseases

A combination of preclinical and translationally driven studies has solidified TAAR1 as a key node in the regulation of dopaminergic signaling and holds great promise as a therapeutic target for mental illness, addiction, and sleep disorders.

Trace Amine-Associated Receptors as Novel Therapeutic Targets for Immunomodulatory Disorders

A model whereby TAARs may be considered as a novel therapeutic target for disorders associated with dysregulated immune responses to environmental factors is developed, hypothesizing that altered trace amine homeostasis results in hyperactivity of the immune system.

Trace Amine-Associated Receptor 1 (TAAR1): A new drug target for psychiatry?

Identification of a Potent Human Trace Amine-Associated Receptor 1 Antagonist.

RTI-7470-44 provides a promising hTAAR1 antagonist probe that can be used to study TAAR1 pharmacology and the potential therapeutic role in hypodopaminergic diseases such as PD.

Trace amine associated receptor 1 (TAAR1) modulators: a patent review (2010-present)

The discovery of TAAR receptors has allowed better investigation of the role played by TAs, not only as secondary neuromodulators, but also as neurotransmitters, even if it should still be completely clarified.

Therapeutic Potential of TAAR1 Agonists in Schizophrenia: Evidence from Preclinical Models and Clinical Studies

Unmet needs in schizophrenia, the current state of knowledge in TAAR1 circuit biology and neuropharmacology, including preclinical behavioral, imaging, and cellular evidence in glutamatergic, dopaminergic and genetic models linked to the pathophysiology of psychotic, negative and cognitive symptoms are reviewed.

Biochemical and Functional Characterization of the Trace Amine-Associated Receptor 1 (TAAR1) Agonist RO5263397

RO5263397 not only increases cAMP levels at very low concentrations but also can induce the phosphorylation of ERK and CREB in a concentration- and time-dependent manner, which provides new insight on intracellular signaling pathway and other neurotransmitter receptors modulated by TAAR1 receptor activation.

Trace Amine-Associated Receptor 1 as a Target for the Development of New Antipsychotics: Current Status of Research and Future Directions

If trials of TAAR-1 modulators, and other novel-mechanism targets for schizophrenia that are under active study, continue to show positive results, the definition of an antipsychotic may need to be expanded beyond the D2R target in the near future.



Further Insights Into the Pharmacology of the Human Trace Amine‐Associated Receptors: Discovery of Novel Ligands for TAAR1 by a Virtual Screening Approach

An homology model for the hTAAR1 was used and several agonists and one antagonist, with activities in the low micromolar range were found, which could represent the starting point for the development of more potent and selective TAAR1 ligands.

Insights into the Structure and Pharmacology of the Human Trace Amine‐Associated Receptor 1 (hTAAR1): Homology Modelling and Docking Studies

A homology model for the hTAAR1 receptor was derived and an opportunity to reasonably identify the h TAAR1 key residues involved in ligand recognition and thus define important starting points to design new agonists was provided.

Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.

The successful expression of human and mouse TAAR1 and the characterization of their responses to various natural and synthetic agonists raise new possibilities about the mechanism of some of the imidazoline-related agents.

A renaissance in trace amines inspired by a novel GPCR family.

The potential of trace amines and their receptors for treating neurological and psychiatric diseases.

  • M. D. Berry
  • Biology
    Reviews on recent clinical trials
  • 2007
The aim of the current article is to review the previous studies linking trace amines to human pathology in the context of the recently discovered trace amine receptors and evidence of the existence of Trace amine receptor polymorphisms and mutations associated with such disorders.

International Union of Pharmacology. LXXII. Recommendations for Trace Amine Receptor Nomenclature

This review proposes an official nomenclature designating TAAR1 as the trace amine 1 receptor following the convention of naming receptors after the endogenous agonist, abbreviated to TA1 where necessary.

Trace Amines and the Trace Amine-Associated Receptor 1: Pharmacology, Neurochemistry, and Clinical Implications

TAAR1 is uniquely positioned to exert direct control over DA and 5-HT neuronal firing and release, which has profound implications for understanding the pathophysiology of, and therefore designing more efficacious therapeutic interventions for, a range of neuropsychiatric disorders that involve aminergic dysregulation.

The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia

Trace amines have been implicated in a number of neuropsychiatric disorders including depression and schizophrenia. Although long known to modulate neurotransmission indirectly through the release of